Advertisement

Sensitivity of a cAMP PDE to Rolipram in Different Organs

  • Herbert H. Schneider
  • Gudrun Pahlke
  • Ralph Schmiechen
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 135)

Abstract

Manipulation of cAMP-dependent mechanisms in aminergic transmission by selective phosphodiesterase (PDE) inhibitors may provide a novel therapetic approach for the management of depression (Wachtel, 1983). The PDE inhibitor rolipram has been shown in recent clinical trials to possess antidepressant activity (Horowski and Sastre, 1985). Antidepressant drug therapy needs several days before relief of symptoms is observed. Time-dependent neuronal adaptation processes may be based on an altered function of regulatory proteins, as e.g. resulting from protein phosphorylation. The therapeutic effect following rolipram treatment could therefore be explained by a mechanism involving a cAMP dependent protein kinase.

Keywords

Antidepressant Activity cAMP Dependent Protein Kinase Selective Phosphodiesterase Monophosphate Phosphodiesterase Crude Organ Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bruns, R.F., Lawson-Wendling, K., and Pugsley, T.A., 1983, A rapid filtration assay for soluble receptors using polyethy- lenimine-treated filters. Anal. Biochem., 132:74.PubMedCrossRefGoogle Scholar
  2. Horowski, R., and Sastre, M., 1985, Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports, Curr. Therapeutic Res., 38:23.Google Scholar
  3. Marks, F., and Raab, I., 1974, The second messenger system of mouse epidermis, Biochim. Biophs. Acta, 34:368.Google Scholar
  4. Schneider, H.H., 1984, Brain response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation, Biochem. Pharmacol., 33:1690.PubMedCrossRefGoogle Scholar
  5. Schneider H.H., Schmiechen, R., Brezinski, M., and Seidler, J., 1986, Stereospecific binding of the antidepressant rolipram to brain protein structures, Europ. J. Pharmacol., 127:105.CrossRefGoogle Scholar
  6. Schwabe, U., Miyake, M., Ohga, Y., and Daly, J.W., 1976, 4-(3-Cyclopentyloxy-4-methoxyphenyl)-pyrrolidone (ZK 62711): A potent inhibitor of adenosine cyclic 35-monophosphate phosphodiesterase in homogenates and tissue slices from rat brain, Mol. Pharmacol., 12:900.PubMedGoogle Scholar
  7. Wachtel, H., 1983, Potential antidepressant activity of rolipram and other selective cyclic adenosine 35-monophosphate phosphodiesterase inhibitors. Neuropharmacology, 22:267.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Herbert H. Schneider
    • 1
  • Gudrun Pahlke
    • 1
  • Ralph Schmiechen
    • 1
  1. 1.Research Laboratories of Schering AGBerlin (West) and BergkamenGermany

Personalised recommendations